The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated follicular and marginal zone lymphomas.
The approval—the first of a combination regimen for patients with these indolent forms of non-Hodgkin lymphoma that does not include chemotherapy—was based on the AUGMENT (ClinicalTrials.gov Identifier: NCT01938001) and MAGNIFY (ClinicalTrials.gov Identifier: NCT01996865) phase 3 trials.
In AUGMENT, 358 patients with relapsed or